REG - Aptamer Group PLC - AGM Statement

AptamerAnnouncement

01/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA1769Ia&default-theme=true

RNS Number : 1769I  Aptamer Group PLC  01 December 2022

1 December 2022

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Annual General Meeting Statement

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, announces the following
update from Dr Arron Tolley, Chief Executive Officer, in advance of the
Company's Annual General Meeting ('AGM') to be held today at 1:30pm GMT.

 

"2022 has been a transformational year for Aptamer Group with significant
progress made towards our goal to capitalise on the market opportunity with
aptamers across the life science sector. I am pleased to say that we are
deploying the funds raised at IPO effectively and are now settling into our
new, larger premises, which we were delighted to officially open on 25
November 2022
(https://polaris.brighterir.com/public/aptamer_group/news/rns/story/rm31pvx)
and celebrate the expansion of our business.

 

"Today I am pleased to report a selection of new contract wins which have the
potential for future downstream royalties and milestone payments.

 

"In our Aptamer Therapeutics business, we have entered the second phase of our
collaboration with Cancer Research UK to develop the delivery vehicle portion
of the bispecific therapeutic Optimer binder for the treatment of Chronic
Myelomonocytic Leukaemia (CMML) and other myeloid malignancies. We've also
signed an early stage deal to develop Optimers to block the activity of
naturally occurring antibodies within the body for use as a potential therapy
to prevent transplant rejection. The binders we generate may then support the
development of a companion diagnostic panel, in addition to therapeutic use.

 

"Our Aptamer Solutions business has also seen significant progress since our
full year results, with numerous new projects underway. Since the publication
of the Group's full year results, we have signed deals with a number of
companies related to the development of Optimer solutions for assays where
antibodies are not meeting their specificity and selectivity requirements.

 

"We are working with a biomarker services company to develop Optimer binders
to support multiplex biomarker assays for mass spectrometry analysis. The
Optimer-based assays will deliver increased sensitivity in identifying and
analysing neurodegenerative disease biomarkers to improve clinical trial
outcomes in drug development.

 

"Finally, we've also signed a deal with Novavax, a vaccine developer for
respiratory diseases, who require Optimers to improve the selectivity and
enable multiplex analysis of their QC assays.

 

"Our healthy deal pipeline demonstrates the clear market opportunity and
demand for Optimers and I'm encouraged that we will continue on our growth
trajectory for the financial year.

 

"To conclude, I would like to thank all the Group's staff and shareholders for
their continuing support, and we look forward to the rest of this financial
year with confidence and enthusiasm."

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
 
     +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Will Hall / Cara
Murphy                        +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer® platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBMBTTMTBJTLT